| MR编号 | SE/H/0153/001 |
|---|
| 药品名称 | Pentavac |
|---|
| 活性成分 | - diphtheria toxoid, adsorbed 30.0 IU
- Haemagglutinin Isolated From Er1k A Equi Brentwood 79 25.0 µg
- haemophilus influenzae type b (strain PBCC 197) capsular oligosaccharide conjugated to diphtheria CMR197 protein 10.0 µg
- Pertussis toxoid 25.0 µg
- Polio virus type 1, inactivated 40.0 IU
- Polio virus type 1, inactivated 32.0 IU
- Polio virus type 2, inactivated 8.0 IU
- tetanus toxoid, adsorbed 40.0 IU
|
|---|
| 剂型 | Powder and suspension for suspension for injection |
|---|
| 上市许可持有人 | Sanofi Pasteur Europe, France |
|---|
| 参考成员国 - 产品名称 | Sweden (SE) Pentavac |
|---|
| 互认成员国 - 产品名称 | - Iceland (IS)
- Denmark (DK)
- Belgium (BE)
- Luxembourg (LU)
- Portugal (PT)
Pentavac - Greece (GR)
- Finland (FI)
|
|---|
| 许可日期 | 1998/08/03 |
|---|
| 最近更新日期 | 2025/02/10 |
|---|
| 药物ATC编码 | - J07CA06 diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus
|
|---|
| 申请类型 | - TypeLevel1：[not specified]
- TypeLevel2：[not specified]
- TypeLevel3：Full Dossier Article 4.8 Di 65/65
- TypeLevel4：[not specified]
- TypeLevel5：[not specified]
|
|---|
| 附件文件下载 | |
|---|
| 市场状态 | Positive |
|---|